Amneal Pharmaceuticals, Inc. (NYSE:AMRX) (“Amneal” or the “Company”) today announced the commercial launch of ALYMSYS® (bevacizumab-maly), a biosimilar referencing Avastin®. ALYMSYS® is a vascular endothelial growth factor inhibitor used in oncology. This product was developed by mAbxience, a global biotech company with over a decade of experience in the development, manufacture, and commercialization of biopharmaceuticals.
Monro Stock Plummets After Q4 Earnings: The Details
Monro, Inc. (NASDAQ:MNRO) shares slid Thursday after reporting lackluster results in the fourth quarter of FY23. The company registered a…
